You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
| Title |
Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses
|
|---|---|
| Published in |
Health technology assessment : HTA / NHS R & D HTA Programme., November 2012
|
| DOI | 10.3310/hta16420 |
| Pubmed ID | |
| Authors |
T Pavey, M Hoyle, O Ciani, L Crathorne, T Jones-Hughes, C Cooper, L Osipenko, M Venkatachalam, C Rudin, O Ukoumunne, R Garside, R Anderson |
| Abstract |
Nilotinib and dasatinib are now being considered as alternative treatments to imatinib as a first-line treatment of chronic myeloid leukaemia (CML). |
Mendeley readers
The data shown below were compiled from readership statistics for 113 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Indonesia | 1 | <1% |
| Canada | 1 | <1% |
| Brazil | 1 | <1% |
| Unknown | 110 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 20 | 18% |
| Researcher | 12 | 11% |
| Student > Bachelor | 10 | 9% |
| Student > Ph. D. Student | 10 | 9% |
| Other | 9 | 8% |
| Other | 23 | 20% |
| Unknown | 29 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 41 | 36% |
| Biochemistry, Genetics and Molecular Biology | 8 | 7% |
| Agricultural and Biological Sciences | 7 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 4% |
| Economics, Econometrics and Finance | 4 | 4% |
| Other | 14 | 12% |
| Unknown | 34 | 30% |